Free tool
FAERS Monitor: Triumeq Pd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215413 or its brand name (Triumeq Pd, Abacavir Sulfate, Dolutegravir Sodium, Lamivudine). Reports on generic versions are filed under their own applications.
Reports
1
Serious
1
100% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- aggression1
- inappropriate schedule of product administration1
- product dose omission issue1
- product use in unapproved indication1
- psychotic disorder1
- substance use1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| substance use | 1 | 13496.3 | 12842.9 | 3,371 |
| psychotic disorder | 1 | 712.4 | 704.3 | 177 |
| aggression | 1 | 420.3 | 416.6 | 104 |
| inappropriate schedule of product administration | 1 | 116.7 | 116.2 | 28 |
| product use in unapproved indication | 1 | 84.9 | 84.5 | 20 |
| product dose omission issue | 1 | 71.5 | 71.3 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.